1
John L Faul, Toshihiko Nishimura, Peter N Kao, Ronald G Pearl: Implantable arterio-venous shunt devices and methods for their use. Rox Medical, James M Heslin, Adam W Bell, Matthew R Kaser, December 8, 2009: US07628768 (18 worldwide citation)

A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a bloo ...


2
John L Faul, Toshihiko Nishimura, Peter N Kao, Ronald G Pearl: Arterio-venous shunt devices. The Board of Trustees of the Leland Stanford Junior University, Adam Bell, James Heslin, Matthew Kaser, November 1, 2011: US08048016 (10 worldwide citation)

A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a bloo ...


3
Raul E Perez, Paul V Goode, Peter I Hong, Steven Diianni, Luis Jose Malave, Brad Stengel, John L Faul: Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch. Elira, Novel IP, November 6, 2018: US10118035

A wearable device for suppressing appetite or hunger in a patient includes a microprocessor, electrical stimulator and at least one electrode configured to deliver electrical stimulation to the epidermis, through a range of 0.1 mm to 10 mm or a range of 0.1 mm to 20 mm of the dermis, of a T2 frontal ...


4
Raul E Perez, Paul V Goode, Peter I Hong, Steven Diianni, Luis Jose Malave, Brad Stengel, John L Faul: Systems and methods for enabling appetite modulation and/or improving dietary compliance using an electro-dermal patch. Elira, Novel IP, December 4, 2018: US10143840

A wearable device for suppressing appetite or hunger in a patient includes a microprocessor, electrical stimulator and at least one electrode configured to deliver electrical stimulation to the epidermis, through a range of 0.1 mm to 10 mm or a range of 0.1 mm to 20 mm of the dermis, of a T2 frontal ...


5
Raul E Perez, Peter I Hong, Steven Diianni, Luis Jose Malave, Brad Stengel, John L Faul: Systems and methods for enabling appetite modulation and/or improving dietary compliance using percutaneous electrical neurostimulation. Elira, Novel IP, December 18, 2018: US10154922

A wearable, percutaneous device for suppressing appetite or hunger in a patient includes a microprocessor, electrical stimulator and at least one percutaneous electrode implanted and configured to deliver electrical stimulation through the patient's skin. The percutaneous device includes a pad and a ...


6
John L Faul, Toshihiko Nishimura, Peter N Kao, Ronald G Pearl: Implantable arterio-venous shunt devices and methods for their use. The Board of Regents of The Leland Stanford Junior University, Bell & Associates, December 27, 2007: US20070299384-A1

A long-term implantable arterio-venous shunt device or creation of a fistula is provided that can be used as a therapeutic method for treating chronic obstructive pulmonary disease (COPD). The shunt device is implanted between an artery and a vein, preferably between a peripheral artery and the infe ...


7
John L Faul, Toshihiko Nishimura, Peter N Kao, Ronald G Pearl: Implantable arterio-venous shunt devices and methods for their use. Bell & Associates, May 19, 2005: US20050107733-A1

A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a bloo ...


8
Peter N Kao, Ronald G Pearl, Toshihiko Nishimura, John L Faul: Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases. Bozicevic Field & Francis, June 2, 2005: US20050119330-A1

Methods of treating lung proliferative vascular disorders by administering an antiproliferative agent are provided. A preferred antiproliferative agent is a HMG-CoA reductase inhibitor, preferably simvastatin. Vascular occlusion in the pulmonary arteries of the patient is reduced as a result of the ...


9
John L Faul, Toshihiko Nishimura, Peter N Kao, Ronald G Pearl: Implantable arteriovenous shunt device. Lumen Intellectual Property Services, December 9, 2004: US20040249335-A1

A long-term implantable arteriovenous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a blood ...


10
John L Faul, Toshihiko Nishimura, Peter N Kao, Ronald G Pearl: Arterio-venous shunt devices. Bell & Associates, June 18, 2009: US20090156978-A1

A long-term implantable arterio-venous shunt device is provided that can be used as a therapeutic method. The shunt device is implanted between an artery and a vein, preferably between the aorta and the inferior vena cava. The shunt device decreases the systemic vascular resistance and allows a bloo ...